What The National Organization for Rare Disorders, Inc. (NORD) does

NORD is a 501(c)(3) national federation founded in 1983 in the wake of the Orphan Drug Act to serve as the umbrella advocacy and infrastructure body for the U.S. rare disease community. It supports more than 30 million Americans affected by rare diseases through a network of 340+ patient advocacy organizations serving over half a million patients, 46 designated Rare Disease Centers of Excellence, and a 140,000+ annual-call helpline. Its program portfolio spans patient assistance (medication, co-pay, travel for clinical trials, free drug — pioneered in 1987), seed research grants (since 1989, contributing to at least two FDA-approved therapies), policy advocacy through the Rare Action Network and 25 state-level Rare Disease Advisory Councils, and community events including Rare Disease Day, the Scientific Symposium, and the Breakthrough Summit.

The technology backbone centers on the IAMRARE Registry Platform and its October 2025-launched mobile app, which power disease-specific patient registries such as LGS-CORE (Lennox-Gastaut Syndrome, global) and the Facial Pain Registry (740 participants). The Rare Disease Database covers 1,200+ conditions with expert review, and the March 2026 OpenEvidence partnership adds 3,000+ AI-synthesized summaries updated monthly. The Living Rare Study is the first large-scale, long-term U.S. study tracking rare disease patient and caregiver experiences. CME programming is delivered through Medlive, reaching 76,000+ clinicians across 140+ programs.

Revenue is diversified across individual donations (including the $1,000+ Rare Giving Society tier), corporate partnerships via a Corporate Council (with pharma/biotech employees structurally excluded from the Board), federal and state government grants, and program-related contributions. GTM is community-led — anchored by member organizations, Centers of Excellence, and awareness events — with an event-driven component through annual summits and Rare Disease Day. NORD operates from offices in Norwell, MA (headquarters), Danbury, CT, Newport Coast, CA, and Washington, DC, with 51–100 employees.

Name

The National Organization for Rare Disorders, Inc. (NORD)

Legal name

National Organization for Rare Disorders, Inc.

Website

https://rarediseases.org

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

51–100 employees

Short description

The National Organization for Rare Disorders (NORD) is a 501(c)(3) federation founded in 1983 that serves the 30+ million Americans with rare diseases through 340+ member advocacy organizations, 46 Centers of Excellence, the IAMRARE registry platform, patient assistance, research grants, and federal and state policy advocacy.

Ownership category

akta.pro rank

Product category

Rare Disease Patient Advocacy Services

NAICS

Individual and Family Services (6241), Other Individual and Family Services (624190), Social Assistance (624)

SIC

Services-Social Services (8300), Services-Membership Organizations (8600), Services-Health Services (8000)

akta.pro primary industry

Rare Disease & Special Needs Support Organizations (BPAGACAM)

akta.pro secondary industries

Patient Advocacy, Navigation & Access to Care (BPAGACAH), Disease Registries (Cancer, Immunization, Rare Disease, etc.) (HLAJAJAE), Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)

Keywords

• Rare disease advocacy
• Patient assistance programs
• Patient registry platforms
• Medical education services
• Rare disease research grants

Headquarters

HQ city

Danbury

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Individual Donations: Tax-deductible charitable contributions from individuals supporting NORD's mission. Multiple giving options include one-time gifts, monthly recurring donations, stock donations, IRA qualified charitable distributions, donor-advised fund grants, and planned giving through estates.
2. Corporate Partnerships: Funding and support from pharmaceutical and biotechnology companies through NORD's Corporate Council membership program. While NORD accepts industry funding, it prohibits pharmaceutical/biotech employees from serving on its Board of Directors.
3. Government Grants: Federal funding to support rare disease research and advocacy programs.
4. Rare Giving Society: Recognition program for donors contributing $1,000 or more annually, encouraging higher-level philanthropy.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels10 records

Core offering

NORD operates as a 501(c)(3) nonprofit federation providing patient assistance programs (medication, co-pay, travel, and premium support pioneered in 1987), the IAMRARE patient registry platform with a companion mobile app, and the only network of 46 Rare Disease Centers of Excellence in the U.S. The organization also runs a comprehensive Rare Disease Database covering more than 1,200 conditions, continuing medical education (reaching 76,000+ clinicians via Medlive), federal and state policy advocacy, community-building through 340+ patient advocacy member organizations, AI-powered rare disease summaries (with OpenEvidence, totaling 3,000+ and updated monthly), and seed research grant programs.

Product overview

NORD offers a comprehensive portfolio of programs and services organized as a platform-plus-modules architecture. The core offerings include the IAMRARE® Registry Platform (with companion mobile app) for patient-powered research, a Rare Disease Database covering 1,200+ conditions, a network of 46 Rare Disease Centers of Excellence, Patient Assistance Programs (including medication, co-pay, and travel assistance), RareEdu® online learning platform, and a Rare Disease Video Library. These are complemented by advocacy initiatives including the Rare Action Network®, NORD State Report Card®, and Rare Disease Advisory Councils. NORD also hosts major events including the annual Rare Disease Scientific Symposium, Rare Diseases & Orphan Products Breakthrough Summit®, Living Rare Living Stronger Patient & Family Meeting, and Rare Disease Day® awareness campaign. A notable recent addition is AI-Powered Rare Disease Summaries developed with OpenEvidence, providing 3,000+ rare disease summaries combining AI synthesis with expert review. The organization supports research through seed grants, the Rare Disease Cures Accelerator (RDCA-DAP), and the Living Rare Study® tracking patient experiences. NORD's CME programming, delivered via Medlive partnership, has reached over 76,000 clinicians.

Differentiator

Problem solved

Functional benefit

Brands

• IAMRARE®: Patient registry platform powered by NORD for collecting clinical-grade patient-reported outcomes data to advance rare disease research.
• RareEdu®
• Rare Action Network®
• NORD State Report Card®
• LGS-CORE
• Rare Disease Day®
• Living Rare, Living Stronger®
• Claim Your Care®
• Living Rare Study®

Products and services

• IAMRARE Registry Platform A patient registry platform that enables rare disease patients to share clinical-grade patient-reported outcomes data with researchers worldwide, powering disease-specific registries such as the Facial Pain Registry and the LGS-CORE Study.
• IAMRARE Mobile App Mobile companion app to the IAMRARE Registry Platform that enables rare disease patients and caregivers to contribute to research through faster and higher-quality data collection on iOS and Android devices.
• Rare Disease Database Comprehensive database providing expert-reviewed information on more than 1,200 rare diseases, serving as a primary educational resource for patients, families, and clinicians.
• NORD Rare Disease Centers of Excellence A national network of 46 NORD-designated academic medical and research centers that provide specialized diagnosis, multi-specialty coordinated services, and treatment for rare disease patients across the United States.
• Patient Assistance Programs Comprehensive patient assistance programs providing free medication, co-pay assistance, premium assistance, travel and lodging assistance for clinical trials, and expanded or emergency access support for rare disease patients.
• RareEdu Online Learning Platform Online learning platform providing educational courses on rare diseases for patients, caregivers, medical professionals, students, and the public, hosted at learn.rarediseases.org.
• Continuing Medical Education (CME) Program Accredited continuing medical education courses for healthcare professionals on rare disease recognition, diagnosis, and management, delivered via the Medlive partnership and reaching more than 76,000 clinicians.
• Living Rare Study The first large-scale, long-term U.S. study tracking the evolving experiences of individuals and caregivers impacted by rare diseases, with results shaping NORD programming and policy decisions.
• Rare Disease Cures Accelerator (RDCA-DAP) Data platform that supports rare disease research by providing access to patient-level data and facilitating research collaborations between academia, industry, and regulators.
• AI-Powered Rare Disease Summaries Library of more than 3,000 expert-reviewed rare disease summaries combining AI-powered synthesis of biomedical literature with expert review, offered in clinician-focused and patient-friendly formats and updated monthly.
• Research Grant Programs Seed research grants to researchers working in rare diseases, providing funding to collect preliminary data needed to attract future grants and research contracts.
• Patient Organization Mentorship (RareLaunch) Capacity-building and mentorship services for rare disease patient organizations, including the RareLaunch program, NORD Membership Program, and Becoming Research Ready training for new advocacy groups.
• Clinical Trials Assistance Services helping rare disease patients find and participate in clinical trials, including diagnostic testing assistance and travel and lodging support for clinical trial participation.
• Corporate Council Membership Program Membership program bringing together pharmaceutical, biotechnology, and other companies committed to supporting the rare disease community through collaboration, resource sharing, and corporate philanthropy.

Quantifiable outcome

• 140,000+ calls and emails handled annually through NORD's helpline
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Facial Pain AssociationcoreStrategic or Co-development Partner · 10 June 2026The Facial Pain Association developed its Facial Pain Registry in partnership with NORD on the IAMRARE platform. The registry has enrolled 740 participants who completed all three available surveys, attracting interest from academic researchers and pharmaceutical companies. Formal research proposal submissions are expected by fall 2026.
• Kedrion BiopharmaminorGTM or Marketing Partner · 4 May 2026Kedrion Biopharma collaborated with NORD on Plasminogen Deficiency Awareness Day, hosting global virtual and in-person events to promote earlier diagnosis of the ultra-rare genetic disorder PLGD-1. NORD is recognized as one of Kedrion's patient advocacy organization collaborators.
• Plasminogen Deficiency FoundationminorGTM or Marketing Partner · 4 May 2026The Plasminogen Deficiency Foundation collaborated with NORD and Kedrion Biopharma on Plasminogen Deficiency Awareness Day activities to promote awareness and earlier diagnosis of PLGD-1.
• OpenEvidencecoreTechnology or Integration · 13 March 2026NORD partnered with OpenEvidence to expand access to trusted, expert-reviewed rare disease information for clinicians, patients, and families worldwide. The collaboration combines AI-powered synthesis of biomedical literature with expert review to build a library of more than 3,000 rare disease summaries in clinician-focused and patient-friendly formats. Summaries are updated monthly as evidence evolves.
• LGS Foundation (Lennox-Gastaut Syndrome Foundation)coreStrategic or Co-development Partner · 24 February 2026The LGS Foundation partnered with NORD to launch the LGS-CORE Study, a global patient registry designed to collect comprehensive data on patients living with Lennox-Gastaut Syndrome. The registry addresses critical gaps in understanding the disease experience to advance drug development and treatment options. The initiative was designed with input from scientists and patient-families.
• NIH (National Institutes of Health)coreStrategic or Co-development Partner · 23 February 2026NORD collaborates with NIH on rare disease research initiatives. NIH Director Dr. Jay Bhattacharya was a headline speaker at NORD's 2026 Rare Disease Scientific Symposium. NORD also partners on the Rare Disease Cures Accelerator (RDCA-DAP) and the All of Us Study.
• FDAcoreStrategic or Co-development Partner · 23 February 2026NORD works with FDA on regulatory policy for rare disease therapies. NORD hosted a congressional briefing following FDA's release of draft guidance on a 'plausible mechanism' framework for rare disease therapy approval. FDA leadership participates in NORD's annual Breakthrough Summit.
• MedlivecoreTechnology or Integration · 6 January 2026NORD extended its exclusive continuing medical education partnership with Medlive for over six years. The collaboration has delivered more than 140 digital education programs reaching over 76,000 clinicians, patients, and caregivers, with 93% of participating clinicians reporting positive practice changes. New initiatives include applying real-world data to generate evidence of care changes and developing innovative formats.
• EURORDIS (European Organisation for Rare Diseases)coreStrategic or Co-development PartnerEURORDIS is a key international partner. NORD represents the United States on committees for Rare Diseases International (RDI) and Rare Disease Day.
• Japanese Patient Association (JPA)minorStrategic or Co-development PartnerInternational alliance partner for rare disease coordination globally.
• Rare Diseases International (RDI)coreStrategic or Co-development PartnerNORD represents the United States on the committees of Rare Diseases International, an organization coordinating rare disease efforts globally.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• EURORDIS (European Organisation for Rare Diseases): European equivalent of NORD — a federation of rare disease patient organizations running policy advocacy, research support, and patient programs across Europe. Most directly comparable peer given shared mission, federation model, and joint Rare Disease Day leadership.
• EveryLife Foundation for Rare Diseases: U.S. rare disease advocacy nonprofit focused on accelerating biotech innovation and FDA policy reform for rare disease therapies. Directly comparable given shared federal advocacy and policy focus, including work on newborn screening and orphan drug development.
• Muscular Dystrophy Association (MDA): Major U.S. health nonprofit supporting research, care, and advocacy across multiple rare neuromuscular diseases. Comparable federation-adjacent model covering many rare diseases under one umbrella, with Centers of Excellence clinics and research grants analogous to NORD's.
• Cystic Fibrosis Foundation: Single-disease rare disease foundation that operates an accredited care center network (analogous to NORD's 46 Centers of Excellence), funds research, runs a patient registry, and provides patient assistance. Closest single-disease comparable in operating model and scale.
• Global Genes: U.S. rare disease nonprofit focused on patient advocacy, education, and supporting rare disease communities. Comparable in mission, target constituency, and nonprofit funding model, with overlapping programs in awareness, patient services, and capacity building.

Emerging players

• National Organization for Rare Disorders / RDI (Rare Diseases International): Global umbrella that NORD participates in; coordinates rare disease advocacy across national alliances worldwide. Overlaps with NORD in international policy and Rare Disease Day coordination.
• ALS Association: Major single-disease U.S. nonprofit running research, care centers, advocacy, and patient services for ALS. Comparable in federation-of-chapters model, federally engaged policy work, and large donor base.

Broad incumbents

• American Cancer Society: Large U.S. health nonprofit that pioneered the disease-association model combining research grants, patient services, advocacy, and an information database. Comparable in operating playbook (research funding + helpline + database + advocacy), though broader in disease scope and orders of magnitude larger.
• National Health Council: U.S. nonprofit umbrella organization representing hundreds of patient advocacy groups and health-related nonprofits. Overlaps with NORD in member services, policy advocacy, and capacity building, but covers all chronic conditions, not just rare diseases.

Others

• NIH NCATS (National Center for Advancing Translational Sciences): U.S. government entity that partners with NORD on RDCA-DAP and rare disease research infrastructure. Comparable as a funder and infrastructure partner in rare disease translational research rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/national-organization-for-rare-disorders
• Instagraminstagram.com/nord_rare
• Facebookfacebook.com/NationalOrganizationforRareDisorders
• YouTubeyoutube.com/channel/UC7_8G5d8Uq5y5QJq8J8aKgw
• Xx.com/rarediseases

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The National Organization for Rare Disorders, Inc. (NORD)